Synergia Medical's Innovative Device Implanted in First Patients

Synergia Medical has successfully implanted its groundbreaking neurostimulation device, NAO.VNS, in the first two patients as part of a first-in-human study for treating epilepsy. Conducted at sites in Belgium and Germany, the trial explores this innovative vagus nerve stimulation therapy, which uses photonic power transfer instead of traditional copper wires, making it compatible with MRI scans.

Epilepsy affects millions worldwide, with nearly 30% of patients unable to control seizures through medication alone. Synergia’s technology offers a promising solution by delivering precise electrical pulses to stabilize brain activity, while also allowing continuous monitoring via MRI. The study aims to evaluate the safety and efficacy of this novel approach in 10 patients with drug-resistant epilepsy.